Phase 3 Trial Comparing IRE and SBRT for Intermediate-Risk Prostate Cancer
Summary
NIH registered a Phase 3 clinical trial (NCT07548164) comparing two boost approaches for intermediate-risk prostate cancer patients receiving standard stereotactic body radiotherapy (SBRT): the investigational NanoKnife System using irreversible electroporation (IRE) versus continued standard SBRT boost. The trial is categorized as Phase 3 and appears in the ClinicalTrials.gov registry. This registration documents a new clinical study and does not itself impose compliance obligations on sponsors, investigators, or institutions.
“In this study we will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for people with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The document is a ClinicalTrials.gov registry entry for a new Phase 3 clinical trial (NCT07548164) titled 'Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer.' The trial will evaluate whether irreversible electroporation (IRE) delivered via the NanoKnife System is as effective as standard SBRT boost for intermediate-risk prostate cancer patients. The registration provides the trial identifier, phase classification (Phase 3), conditions (Prostate Cancer), interventions (NanoKnife System and Stereotactic Body Radiation Therapy), and start date (April 23, 2026).
For sponsors, contract research organizations, and clinical investigators, this registry entry signals that a new Phase 3 comparative effectiveness study in prostate cancer radiotherapy is active. Sites interested in participating should consult the original ClinicalTrials.gov record for eligibility criteria, enrollment targets, investigator contacts, and site locations. The trial registration itself does not create regulatory obligations but establishes the official public record of the study's scope and design.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
Phase 3 NCT07548164 Kind: PHASE3 Apr 23, 2026
Abstract
In this study we will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for people with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).
Conditions: Prostate Cancer
Interventions: NanoKnife System, Stereotactic Body Radiation Therapy
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.